SCHEMBL3787402

SCHEMBL3787402

CCOc1ccc(-c2ccccc2)cc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.59
ALDH1A1 P00352 5/20 0.59
KDM4E B2RXH2 5/20 0.59
HSD17B10 Q99714 4/20 0.59
POLB P06746 3/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
HPGD P15428 2/20 0.59
MAPK1 P28482 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
TP53 P04637 2/20 0.54
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
USP2 O75604 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CREBBP Q92793 1/20 0.50
GAA P10253 3/20 0.47
HTT P42858 2/20 0.47
LMNA P02545 1/20 0.47
HSP90AA1 P07900 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3789389 0.87 MAPT (0.61) MAPTALDH1A1KDM4EHSD17B10POLB
SCHEMBL3785868 0.86 MAPT (0.56) MAPTALDH1A1KDM4EHSD17B10POLB
SCHEMBL3781455 0.86 ALDH1A1 (0.82) MAPTALDH1A1KDM4EHSD17B10POLB
SCHEMBL27814160 0.83 KDM4E (0.60) MAPTALDH1A1KDM4EHSD17B10POLB
SCHEMBL3785716 0.83 ALDH1A1 (0.59) MAPTALDH1A1KDM4EHSD17B10POLB
SCHEMBL3793244 0.81 MRGPRX4 (0.48) MAPTALDH1A1KDM4EHSD17B10MEN1
SCHEMBL5835000 0.81 HPSE (0.56) MAPTALDH1A1KDM4EHSD17B10POLB
SCHEMBL1911874 0.80 MRGPRX4 (0.54) MAPTALDH1A1KDM4EHSD17B10POLB
SCHEMBL330530 0.79 ALDH1A1 (0.55) MAPTALDH1A1KDM4EHSD17B10MEN1
SCHEMBL30196061 0.79 KDM4E (0.52) MAPTALDH1A1KDM4EHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025100475-A1 COMPOSITION FOR IMAGE RECORDING AND METHOD FOR PRODUCING SAME キヤノン株式会社 2025-05-15 WO disclosed
CN-113677666-A Substituted bicyclic compounds as farnesoid X receptor modulators 百时美施贵宝公司 2021-11-19 CN disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
CN-1678321-A Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS INC (US) 2005-10-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 MAPT 3312/4885ALDH1A1 4339/4885KDM4E 2606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.